HomeAI · summaries
Storia in 2 fonti
Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments - Regenxbio (NASDAQ:RGNX)
REGENXBIO announced positive long-term sura-vec trial data for wet AMD and diabetic retinopathy, alongside a $100 million offering.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
tipranks.com
Regenxbio presents long-term data for surabgene lomparvovec
Regenxbio (RGNX) announced positive data from long-term follow-up studies of investigational surabgene lomparvovec in wet AMD using subretinal d...
- ·
benzinga.com
Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments - Regenxbio (NASDAQ:RGNX)
REGENXBIO announced positive long-term sura-vec trial data for wet AMD and diabetic retinopathy, alongside a $100 million offering.